BOLERO-2 Trial: Everolimus in Metastatic Breast Cancer
Published Online: Thursday, June 13, 2013
For High-Definition, ClickInterest in treatment with novel combinations of targeted agents and hormonal therapies in hormone receptor-positive breast cancer caused the establishment of several unique clinical trials, including BOLERO-2, suggests moderator Adam M. Brufsky, MD, PhD.
Initially, some researchers did not believe the combination of an mTOR inhibitor and hormonal therapy would prove to be effective. This skepticism was partially based on earlier research into the mTOR inhibitor temsirolimus, which did not demonstrate efficacy in this space, Brufsky suggests. However, since this initial setback, the treatment paradigm changed to include more exposure to aromatase inhibitors (AIs) and longer durations of treatment with hormonal therapies, explains Hope S. Rugo, MD. Also, the mTOR inhibitor dose in initial trials may not have been correct, based on levels of stomatitis, a common side effect of mTOR inhibition.
Initially, research into the mTOR inhibitor everolimus was undertaken in the neoadjuvant setting, looking for a potential biomarker, explains Rugo. In this trial, a great deal of information was uncovered about treatment with everolimus, including the occurrence of interstitial pneumonitis and other side effects. Additionally, the trial demonstrated a slight clinical benefit and a significant drop in Ki67.
The rationale to explore mTOR inhibition in the metastatic setting stemmed from information on the PI3K pathway and the increased mutational burden in advanced disease. The phase III BOLERO-2 trial was undertaken to explore this rationale further. In the trial, patients were randomized 2:1 to receive exemestane plus everolimus or exemestane and placebo. Most patients enrolled were chemotherapy naive and a large amount had visceral disease, which generally indicates the need for treatment with chemotherapy, Rugo notes.
In the trial, there was a large difference in progression-free survival favoring treatment with everolimus. Interestingly, Rugo explains, the progression free survival benefit was less pronounced by local assessment than by independent central evaluation, which is not generally the case.
Examining the toxicity profile, the main concern that has been raised was the occurrence of stomatitis. In general, Rugo notes, grade 3 stomatitis occurred in 8% of patients. However, Joyce A. O'Shaughnessy, MD, recommends the utilization of a steroid mouthwash as a preventive option. This approach seems to be largely effective in most patients, Rugo and O'Shaughnessy agree.
View More From This Discussion
Sara Hurvitz, MDAssistant Professor & Director,
Hematology/Oncology Breast Cancer Program, UCLA's Jonsson Comprehensive Cancer Center, Los Angeles, California
Joyce A. O’Shaughnessy, MDCo-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology, PA/US Oncology,
Edith A. Perez, MDDeputy Director of the Mayo Clinic Cancer Center, Director of the Breast Cancer Translational Genomics Program and the Breast Program at Mayo Clinic,
Hope S. Rugo, MDProfessor of Medicine and Director of the Breast Oncology, Clinical Trials, and Education Program, University of California San Francisco Comprehensive Cancer Center, San Francisco, California
Andrew D. Seidman, MDProfessor of Medicine, Weill Cornell Cancer Center, Attending Physician at Memorial Sloan Kettering Cancer Center,
New York, New York
Most Popular Right Now
Online CME Activities
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.